Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus

23 Aug 2021

Abstract excerpt

Objective Baricitinib, a selective inhibitor for janus kinase (JAK) 1 and JAK2, is approved for use in rheumatoid arthritis. Systemic lupus erythematosus (SLE) is recently regarded as a potential candidate targeted by JAK inhibitors because of the relationship between its pathogenesis and JAK/signal transducer and activator of transcription (STAT) pathway-mediated cytokines such as type I interferons. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis and Cardiovascular Diseases
Share to Galectins and Cancer Biology
Share to Systemic Lupus Erythematosus Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34497607
DOI: 10.3389/fimmu.2021.704526

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus ErythematosusPMID 34497607Read ↗

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathwaysSemantic proximity Read ↗

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity Read ↗

Immune cell alterations in a pristane‐induced lupus model in C57BL/6J miceSemantic proximity Read ↗

Upadacitinib: Mechanism of action, clinical, and translational scienceSemantic proximity Read ↗

Potential benefits of JAK inhibitor therapy in Blau syndrome: a case report.Semantic proximity Read ↗

ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosisSemantic proximity Read ↗

ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosisSemantic proximity Read ↗

Lupus nephritis: the evolving role of novel therapeutics.Semantic proximity Read ↗

Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).Semantic proximity Read ↗

SB431542 alleviates lupus nephritis by regulating B cells and inhibiting the TLR9/TGFβ1/PDGFB signalingSemantic proximity Read ↗

SH3BP2 Deficiency Ameliorates Murine Systemic Lupus ErythematosusSemantic proximity Read ↗

Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in Systemic Lupus ErythematosusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.